JP2011510995A5 - - Google Patents

Download PDF

Info

Publication number
JP2011510995A5
JP2011510995A5 JP2010545168A JP2010545168A JP2011510995A5 JP 2011510995 A5 JP2011510995 A5 JP 2011510995A5 JP 2010545168 A JP2010545168 A JP 2010545168A JP 2010545168 A JP2010545168 A JP 2010545168A JP 2011510995 A5 JP2011510995 A5 JP 2011510995A5
Authority
JP
Japan
Prior art keywords
methyl
pyrazolo
indazol
pyrimidin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010545168A
Other languages
English (en)
Japanese (ja)
Other versions
JP5608099B2 (ja
JP2011510995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/032459 external-priority patent/WO2009097446A1/en
Publication of JP2011510995A publication Critical patent/JP2011510995A/ja
Publication of JP2011510995A5 publication Critical patent/JP2011510995A5/ja
Application granted granted Critical
Publication of JP5608099B2 publication Critical patent/JP5608099B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010545168A 2008-01-30 2009-01-29 ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法 Expired - Fee Related JP5608099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2481308P 2008-01-30 2008-01-30
US61/024,813 2008-01-30
PCT/US2009/032459 WO2009097446A1 (en) 2008-01-30 2009-01-29 Pyrazolopyrimidine pi3k inhibitor compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2011510995A JP2011510995A (ja) 2011-04-07
JP2011510995A5 true JP2011510995A5 (enExample) 2012-03-22
JP5608099B2 JP5608099B2 (ja) 2014-10-15

Family

ID=40548738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545168A Expired - Fee Related JP5608099B2 (ja) 2008-01-30 2009-01-29 ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法

Country Status (7)

Country Link
US (1) US8987280B2 (enExample)
EP (1) EP2252616B1 (enExample)
JP (1) JP5608099B2 (enExample)
CN (1) CN101981037B (enExample)
CA (1) CA2711759A1 (enExample)
ES (1) ES2494365T3 (enExample)
WO (1) WO2009097446A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
US20100015141A1 (en) * 2008-07-21 2010-01-21 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP5731978B2 (ja) * 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2356117B1 (en) * 2008-11-20 2012-09-26 Genentech, Inc. Pyrazolopyridine pi3k inhibitor compounds and methods of use
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
DK2467141T3 (en) 2009-08-17 2019-02-18 Intellikine Llc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
CN102471342A (zh) * 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
CA2804304C (en) * 2010-05-24 2020-02-25 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2593455B1 (en) * 2010-07-14 2015-03-18 F.Hoffmann-La Roche Ag Purine compounds selective for i3 p110 delta, and methods of use
SG10201510347QA (en) 2010-12-16 2016-01-28 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
KR20140078710A (ko) 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX2014013725A (es) 2012-05-23 2015-02-10 Hoffmann La Roche Composiciones y metodos para obtener y utilizar celulas del endodermo y hepatocitos.
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
BR112015014869A2 (pt) * 2012-12-20 2017-07-11 Univ Leuven Kath derivados de pirazolo-pirimidina terapeuticamente ativos
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9783552B2 (en) 2013-12-11 2017-10-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3831833B1 (en) 2015-02-27 2022-10-26 Incyte Holdings Corporation Processes for the preparation of a pi3k inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN105037373B (zh) * 2015-07-13 2018-07-31 北京理工大学 一种合成吡唑并[3,4-d]嘧啶类化合物的方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3071534A1 (en) 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
WO2020063636A1 (zh) * 2018-09-27 2020-04-02 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021050900A1 (en) 2019-09-13 2021-03-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
EP4081528A4 (en) * 2019-12-23 2024-03-13 Sanford Burnham Prebys Medical Discovery Institute ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN116023380B (zh) * 2021-10-26 2024-01-23 沈阳药科大学 一类吡唑并嘧啶衍生物及制备方法和应用
WO2024249380A2 (en) * 2023-05-26 2024-12-05 University Of Vermont And State Agricultural College 1h-pyrazolo[3,4-d]pyrimidin-4-amines as anti-infectious agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR206F (enExample) * 1965-07-20
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
CN1278819A (zh) 1997-09-02 2001-01-03 杜邦药品公司 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
WO2003029209A2 (en) 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
JP2006056882A (ja) * 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物
JP2006056883A (ja) * 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd 含窒素縮合二環式化合物およびその製法
WO2006009245A1 (ja) * 2004-07-23 2006-01-26 Tanabe Seiyaku Co., Ltd. 含窒素縮合二環式化合物
AP2007003923A0 (en) 2004-09-30 2007-02-28 Tibotec Pharm Ltd Hcv inhibiting bi-cyclic pyrimidines
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MX2007007704A (es) 2004-11-23 2007-09-14 Reddy Therapeutics Inc Compuestos heterociclicos biciclicos novedosos, procesos para su preparacion y composiciones que los contienen.
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
JP2007217408A (ja) * 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
DK2024372T3 (da) * 2006-04-26 2010-09-20 Hoffmann La Roche Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2011510995A5 (enExample)
CN103124729B (zh) 作为Axl抑制剂的药物活性化合物
JP5597353B2 (ja) 置換ピラゾール化合物
JP6524221B2 (ja) Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
ES2360933T3 (es) Derivados de heteroarilo condensados.
TWI629266B (zh) 纖維母細胞生長因子受體之抑制劑
KR101192939B1 (ko) 수용체 티로신 키나아제 저해제로서의 피라졸 유도체
US7582645B2 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
JP2022516882A (ja) Ｍａｔ２ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法
RU2008145662A (ru) Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
JP2009535335A5 (enExample)
JP2012512887A5 (enExample)
KR20090129434A (ko) 피리미딘-2,4-디아민 유도체 및 ｊａｋ2 키나제 억제제로서의 이의 용도
JP2023507669A (ja) ピリド［３，４－ｄ］ピリミジン誘導体およびこれを含む治療用薬学組成物
JP2010512337A5 (enExample)
JP2010512338A5 (enExample)
JP2011521968A5 (enExample)
CN106535890A (zh) 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
US20050009845A1 (en) Thienopyrimidine compounds as protein tyrosine kinase inhibitors
JP2016513661A (ja) Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
KR20010050223A (ko) Ｃｒｆ 길항제 및 관련 조성물의 용도
WO2013170770A1 (zh) 具有抗肿瘤活性的乙炔衍生物
RU2015148359A (ru) Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
CZ304767B6 (cs) Substituovaný pyridin a pyridazin, farmaceutická kompozice s jeho obsahem a použití